Trial Profile

MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Cancer; Lymphoma; Multiple myeloma
Focus Therapeutic Use
Acronyms MATCH-Subprotocol B

Most Recent Events

28 Mar 2025 Planned End Date changed from 5 Mar 2025 to 17 Mar 2026.
06 Mar 2024 Planned End Date changed from 31 Dec 2025 to 5 Mar 2025.
18 Sep 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com